DEF: Krystal Biotech Announces 2025 Annual Meeting of Stockholders, Outlines Key Proposals

Krystal Biotech's 2025 annual meeting will address director elections, auditor ratification, and executive compensation.

Summary

• Krystal Biotech will hold its 2025 annual meeting of stockholders virtually on May 16, 2025.
• Stockholders will vote on electing three Class II directors, ratifying KPMG LLP as the independent auditor, and providing an advisory vote on executive compensation.
• The board recommends voting 'FOR' the director nominees, the ratification of KPMG, and the approval of executive compensation.
• The record date for determining stockholders eligible to vote is March 25, 2025.
• Proxy materials are available online, and stockholders can request paper copies.
• The company achieved $290.5 million in net VYJUVEK product revenue for the year ended December 31, 2024.
• The company ended 2024 with cash, cash equivalents and investments of $749.6 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and progress in clinical development, indicating a favorable sentiment.

Positives

• Strong nationwide access and reimbursement for VYJUVEK in the United States since launch and, as of February 2025, positive access determinations have been achieved for 97% of lives covered under commercial and Medicaid plans.
• Secured over 510 reimbursement approvals for VYJUVEK in the United States as of February 2025.
• Strong patient compliance to once weekly treatment while on VYJUVEK, with a 85% compliance rate from launch through December31, 2024, with 97% of dosing occurring in a home setting.
• The EMAs Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for the European Commission (EC) to approve VYJUVEK for the treatment of wounds in patients with DEB who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth.
• In December 2024, we announced an interim safety data update for patients treated with KB407 in the first two dose escalation cohorts, in which we found single and repeat inhaled administration of KB407 to be safe and well tolerated.
• In December 2024, we announced an interim clinical update including safety data for seven patients enrolled in the first two dose escalation cohorts of SERPENTINE-1. Inhaled KB408 was safe and well-tolerated at both tested dose levels and clear evidence of successful SERPINA1 delivery and AAT expression was observed in both patients that underwent bronchoscopies.
• Early evidence of monotherapy activity was observed in the evaluable cohort of 11 patients with heavily pre-treated advanced non-small cell lung cancer, achieving an objective response rate of 27% and a disease control rate of 73% as of data cut-off. Inhaled KB707 was also reported to be safe and generally well tolerated as monotherapy in the 37 patients included in the safety analysis.
• In August 2024, Jeune Aesthetics announced positive interim safety and efficacy results from Cohorts 3 and 4 of the Phase 1 PEARL-1, open label studies evaluating KB301 in the treatment of lateral canthal lines at rest and dynamic wrinkles of the dcollet, respectively.

Future Outlook

The company plans to commercially launch VYJUVEK in the European Union (EU) and Japan in 2025.

Industry Context

Krystal Biotech is operating in the competitive biotechnology and pharmaceutical sectors, focusing on genetic medicines for rare diseases.

Comparison to Industry Standards

• The document mentions a compensation peer group consisting of publicly traded biotechnology and pharmaceutical companies with similar market capitalization and stage of development.
• Specific companies listed include ACADIA Pharmaceuticals, Corcept Therapeutics, PTC Therapeutics, and others.
• The document compares Krystal Biotech's executive compensation practices against this peer group to ensure competitiveness.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key company matters.
• Employees are impacted by the executive compensation decisions.
• Patients with DEB and other rare diseases are impacted by the company's drug development efforts.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will proceed with preparations for the annual meeting on May 16, 2025.
• The company plans to commercially launch VYJUVEK in the European Union (EU) and Japan in 2025.
• The company expects to initiate the registrational study in the first half of 2025.
• The company expects to report clinical data from patients in the third and final cohort in mid-2025.
• The company expects to report results from the SERPENTINE-1 study in the second half of 2025.
• Jeune Aesthetics expects to start a Phase 2 study evaluating KB301 in this indication in the second half of 2025.
• Jeune Aesthetics expects to report top-line results from the study in the second half of 2025.

Key Dates

Keywords

Krystal Biotech, annual meeting, proxy statement, directors, KPMG, executive compensation, VYJUVEK, gene therapy, stockholders, audit committee